• Phone: +1-631-791-1145
  • Email: sales@imarcgroup.com

*As the coronavirus disease (COVID-19) crisis takes over the world, we are continuously tracking the changes in the markets, as well as the purchase behaviours of the consumers globally and our estimates about the latest market trends and forecasts are being done after considering the impact of this pandemic.

Hospital Acquired Disease Testing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026

Market Overview:

The global hospital-acquired disease testing market reached a value of US$ 7.32 Billion in 2020. Hospital acquired infections (HAIs) or nosocomial infections are diseases that are acquired in hospitals and medical clinics. Nosocomial means, infections or diseases originating in a hospital. A person can get such diseases even in the vicinity of a nursing home, rehabilitation center, hospital or any other clinical surroundings. Most people get HAIs when they are in intensive care units (ICUs) and the emergency rooms (ERs). Generally, the incubation period of these diseases vary between 48 hours to 4 days after the individual gets admitted. A major reason behind the cause of hospital acquired diseases is the lack of proper hygiene in the hospital settings by the internal staff. Another reason can be below-par maintenance, complacency by the hospital staff, and a rise in multi-drug resistant organisms (MDROs). Some of the most commonly occurring nosocomial infections include pneumonia, primary bloodstream infections, urinary tract infections, etc. In many cases, it has also been found that these nosocomial infections are sometimes traced to the patients’ own microbiome. It happens when the protective skin layer comes in contact with possible threats and causes infection to occur, especially after surgical operations.

The market for hospital acquired disease testing is currently exhibiting double digit growth rates. Catalyzed by rising population and modernization of the healthcare infrastructure, there has been a significant increase in the number of health care facilities across the globe. This has resulted in a rising incidence of HAIs, driving the demand of hospital acquired disease tests. Moreover, with advanced technologies and scientific innovations, various techniques are now available in the market for preventing, diagnosing, and monitoring HAIs such as microarrays, polymerase chain reaction (PCR), real time location systems (RTLSs), and solid phase hybridization. Techniques such as RTLS makes it easy to prevent HAIs from spreading in both patients and staff. Growing awareness of HAIs among patients and governments enacting regulations that penalize hospitals having a high incidence of HAIs are some of the other factors that are catalyzing the growth of the market. Looking forward, IMARC Group expects the global hospital acquired disease testing market to exhibit strong growth during the next five years.

Market Summary:

  • Based on the indication, the market has been segmented into urinary tract infection, surgical site infection, pneumonia, bloodstream infections, methicillin-resistant staphylococcus aureus and others. Urinary tract infection currently represents the biggest segment.
  • Region-wise, the market has been segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
  • The competitive landscape of the market has also been examined with some of the key players being Abbott Laboratories, Alere, Inc., Becton, Dickinson and Company, bioMérieux SA, F. Hoffmann-La Roche Ltd., Hologic, Inc., QIAGEN, Siemens Healthcare, Diatherix Laboratories, Inc., Meridian Bioscience, Inc., Thermo Fisher Scientific, Inc. (Life Technologies Corporation) and Cepheid, Inc.


This report provides a deep insight into the global hospital-acquired disease testing market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the hospital-acquired disease testing market in any manner.

Key Questions Answered in This Report:

The global hospital acquired disease testing market size was valued at US$ 7.32 Billion in 2020.

According to the estimates by IMARC Group, the global hospital acquired disease testing market is expected to witness a CAGR of 18.50% from 2021 to 2026.

Rising incidences of HAIs upon exposure to infected patients, contaminated linens, medical equipment, etc., are currently driving the market for hospital acquired disease testing.

Several technological advancements have led to the introduction of microarrays, solid phase hybridization, polymerase chain reaction (PCR) and real-time location systems (RTLSs) for detecting and monitoring HAIs, thereby representing the one of the key trends in the global hospital acquired disease testing market.

Sudden outbreak of the COVID-19 pandemic has led to the rising demand for advanced and effective testing devices for hospital acquired diseases based on the increasing risk of coronavirus contraction upon hospital visits.

On the basis of the indication, the market has been bifurcated into urinary tract infection, surgical site infection (SSI), pneumonia, bloodstream infections, methicillin-resistant staphylococcus aureus (MRSA), and others. Amongst these, urinary tract infection (UTI) holds the majority of the total market share.

Region-wise, the market has been classified into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America, where North America dominates the global market.

The key companies in the global hospital acquired disease testing market are Abbott Laboratories, Alere, Inc., Becton, Dickinson and Company, bioMérieux SA, F. Hoffmann-La Roche Ltd., Hologic, Inc., QIAGEN, Siemens Healthcare, Diatherix Laboratories, Inc., Meridian Bioscience, Inc., Thermo Fisher Scientific, Inc. (Life Technologies Corporation) and Cepheid, Inc.

1    Preface
2    Scope and Methodology

    2.1    Objectives of the Study
    2.2    Stakeholders
    2.3    Data Sources
        2.3.1    Primary Sources
        2.3.2    Secondary Sources
    2.4    Market Estimation
        2.4.1    Bottom-Up Approach
        2.4.2    Top-Down Approach
    2.5    Forecasting Methodology
3    Executive Summary
4    Introduction

    4.1    Overview
    4.2    Key Industry Trends
5    Global Hospital Acquired Disease Testing Market
    5.1    Market Overview
    5.2    Market Performance
    5.3    Impact of COVID-19
    5.4    Market Breakup by Indication
    5.5    Market Breakup by Region
    5.6    Market Forecast
    5.7    SWOT Analysis
        5.7.1    Overview
        5.7.2    Strengths
        5.7.3    Weaknesses
        5.7.4    Opportunities
        5.7.5    Threats
    5.8    Value Chain Analysis
    5.9    Porters Five Forces Analysis
        5.9.1    Overview
        5.9.2    Bargaining Power of Buyers
        5.9.3    Bargaining Power of Suppliers
        5.9.4    Degree of Competition
        5.9.5    Threat of New Entrants
        5.9.6    Threat of Substitutes
    5.10    Price Analysis
6    Market Breakup by Indication
    6.1    UTI (Urinary Tract Infection)
        6.1.1    Market Trends
        6.1.2    Market Forecast
    6.2    SSI (Surgical Site Infection)
        6.2.1    Market Trends
        6.2.2    Market Forecast
    6.3    Pneumonia
        6.3.1    Market Trends
        6.3.2    Market Forecast
    6.4    Bloodstream Infections
        6.4.1    Market Trends
        6.4.2    Market Forecast
    6.5    MRSA (Methicillin-Resistant Staphylococcus Aureus)
        6.5.1    Market Trends
        6.5.2    Market Forecast
    6.6    Others
        6.6.1    Market Trends
        6.6.2    Market Forecast
7    Market Breakup by Region
    7.1    North America
        7.1.1    Market Trends
        7.1.2    Market Forecast
    7.2    Europe
        7.2.1    Market Trends
        7.2.2    Market Forecast
    7.3    Asia Pacific
        7.3.1    Market Trends
        7.3.2    Market Forecast
    7.4    Middle East and Africa
        7.4.1    Market Trends
        7.4.2    Market Forecast
    7.5    Latin America
        7.5.1    Market Trends
        7.5.2    Market Forecast
8    Competitive Landscape
    8.1    Market Structure
    8.2    Key Players
    8.3    Profiles of Key Players
        8.3.1    Abbott Laboratories
        8.3.2    Alere, Inc.
        8.3.3    Becton, Dickinson and Company
        8.3.4    bioMérieux SA
        8.3.5    F. Hoffmann-La Roche Ltd.
        8.3.6    Hologic, Inc.
        8.3.7    QIAGEN
        8.3.8    Siemens Healthcare
        8.3.9    Diatherix Laboratories, Inc.
        8.3.10    Meridian Bioscience, Inc.
        8.3.11    Thermo Fisher Scientific, Inc. (Life Technologies Corporation)
        8.3.12    Cepheid, Inc.

List of Figures

Figure 1: Global: Hospital Acquired Disease Testing Market: Major Drivers and Challenges
Figure 2: Global: Hospital Acquired Disease Testing Market: Sales Value (in Billion US$), 2015-2020
Figure 3: Global: Hospital Acquired Disease Testing Market: Breakup by Indication (in %), 2020
Figure 4: Global: Hospital Acquired Disease Testing Market: Breakup by Region (in %), 2020
Figure 5: Global: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Billion US$), 2021-2026
Figure 6: Global: Hospital Acquired Disease Testing Industry: SWOT Analysis
Figure 7: Global: Hospital Acquired Disease Testing Industry: Porter’s Five Forces Analysis
Figure 8: Global: Hospital Acquired Disease Testing Industry: Porter’s Five Forces Analysis
Figure 9: Global: Hospital Acquired Disease Testing (Urinary Tract Infection) Market: Sales Value (in Million US$), 2015 & 2020
Figure 10: Global: Hospital Acquired Disease Testing (Urinary Tract Infection) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 11: Global: Hospital Acquired Disease Testing (Surgical Site Infection) Market: Sales Value (in Million US$), 2015 & 2020
Figure 12: Global: Hospital Acquired Disease Testing (Surgical Site Infection) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 13: Global: Hospital Acquired Disease Testing (Pneumonia) Market: Sales Value (in Million US$), 2015 & 2020
Figure 14: Global: Hospital Acquired Disease Testing (Pneumonia) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 15: Global: Hospital Acquired Disease Testing (Bloodstream Infections) Market: Sales Value (in Million US$), 2015 & 2020
Figure 16: Global: Hospital Acquired Disease Testing (Bloodstream Infections) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 17: Global: Hospital Acquired Disease Testing (Methicillin-Resistant Staphylococcus Aureus) Market: Sales Value (in Million US$), 2015 & 2020
Figure 18: Global: Hospital Acquired Disease Testing (Methicillin-Resistant Staphylococcus Aureus) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 19: Global: Hospital Acquired Disease Testing (Other Indications) Market: Sales Value (in Million US$), 2015 & 2020
Figure 20: Global: Hospital Acquired Disease Testing (Other Indications) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 21: North America: Hospital Acquired Disease Testing Market: Sales Value (in Million US$), 2015 & 2020
Figure 22: North America: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 23: Europe: Hospital Acquired Disease Testing Market: Sales Value (in Million US$), 2015 & 2020
Figure 24: Europe: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 25: Asia Pacific: Hospital Acquired Disease Testing Market: Sales Value (in Million US$), 2015 & 2020
Figure 26: Asia Pacific: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 27: Middle East and Africa: Hospital Acquired Disease Testing Market: Sales Value (in Million US$), 2015 & 2020
Figure 28: Middle East and Africa: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 29: Latin America: Hospital Acquired Disease Testing Market: Sales Value (in Million US$), 2015 & 2020
Figure 30: Latin America: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Million US$), 2021-2026

List of Tables

Table 1: Global: Hospital Acquired Disease Testing Market: Key Industry Highlights, 2020 and 2026
Table 2: Global: Hospital Acquired Disease Testing Market Forecast: Breakup by Indication (in Million US$), 2021-2026
Table 3: Global: Hospital Acquired Disease Testing Market Forecast: Breakup by Region (in Million US$), 2021-2026
Table 4: Global: Hospital Acquired Disease Testing Market: Competitive Structure
Table 5: Global: Hospital Acquired Disease Testing Market: Key Players

Note: We value your privacy and will never rent or sell your email address. Privacy policy

Purchase Options




$ 2299

REACH OUT TO US

Call us on

( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )


Drop us an email at

sales@imarcgroup.com

Social Links